Binding investigation and preliminary optimisation of the 3-amino-1,2,4-triazin-5(2H)-one core for the development of new Fyn inhibitors

References

• Saito YD, Jensen AR, Salgia R, Posadas EM. Fyn: a novel molecular target in cancer. Cancer 2010;116:1629–37.
   PubMed Web of Science ®Google Scholar
• Osterhout DJ, Wolven A, Wolf RM, et al. Morphological differentiation of oligodendrocytes requires activation of Fyn tyrosine kinase. J Cell Biol 1999;145:1209–18.
   PubMed Web of Science ®Google Scholar
• Schafer I, Muller C, Luhmann HJ, White R. MOBP levels are regulated by Fyn kinase and affect the morphological differentiation of oligodendrocytes. J Cell Sci 2016;129:930–42.
   PubMed Web of Science ®Google Scholar
• Lim SH, Kwon SK, Lee MK, et al. Synapse formation regulated by protein tyrosine phosphatase receptor T through interaction with cell adhesion molecules and Fyn. EMBO J 2009;28:3564–78.
   PubMed Web of Science ®Google Scholar
• Palacios EH, Weiss A. Function of the Src-family kinases, Lck and Fyn, in T-cell development and activation. Oncogene 2004;23:7990–8000.
   PubMed Web of Science ®Google Scholar
• Posadas EM, Al-Ahmadie H, Robinson VL, et al. FYN is overexpressed in human prostate cancer. BJU Int 2009;103:171–7.
   PubMed Web of Science ®Google Scholar
• Charpin C, Secq V, Giusiano S, et al. A signature predictive of disease outcome in breast carcinomas, identified by quantitative immunocytochemical assays. Int J Cancer 2009;124:2124–34.
   PubMed Web of Science ®Google Scholar
• Huang RY, Wang SM, Hsieh CY, Wu JC. Lysophosphatidic acid induces ovarian cancer cell dispersal by activating Fyn kinase associated with p120-catenin. Int J Cancer 2008;123:801–9.
   PubMed Web of Science ®Google Scholar
• Singh MM, Howard A, Irwin ME, et al. Expression and activity of Fyn mediate proliferation and blastic features of chronic myelogenous leukemia. PLoS One 2012;7:e51611.
   PubMed Web of Science ®Google Scholar
• Palacios-Moreno J, Foltz L, Guo A, et al. Neuroblastoma tyrosine kinase signaling networks involve FYN and LYN in endosomes and lipid rafts. PLoS Comput Biol 2015;11:e1004130.
   PubMed Web of Science ®Google Scholar
• Elias D, Ditzel HJ. Fyn is an important molecule in cancer pathogenesis and drug resistance. Pharmacol Res 2015;100:250–4.
   PubMed Web of Science ®Google Scholar
• Lee G, Thangavel R, Sharma VM, et al. Phosphorylation of tau by fyn: implications for Alzheimer’s disease. J Neurosci 2004;24:2304–12.
   PubMed Web of Science ®Google Scholar
• Schenone S, Brullo C, Musumeci F, et al. Fyn kinase in brain diseases and cancer: the search for inhibitors. Curr Med Chem 2011;18:2921–42.
   PubMed Web of Science ®Google Scholar
• Hanke JH, Gardner JP, Dow RL, et al. Discovery of a novel, potent, and Src family-selective tyrosine kinase inhibitor. Study of Lck- and FynT-dependent T cell activation. J Biol Chem 1996;271:695–701.
   PubMed Web of Science ®Google Scholar
• Peckham H, Giuffrida L, Wood R, et al. Fyn is an intermediate kinase that BDNF utilizes to promote oligodendrocyte myelination. Glia 2016;64:255–69.
   PubMed Web of Science ®Google Scholar
• Mao LM, Wang JQ. Dopamine D2 receptors are involved in the regulation of Fyn and metabotropic glutamate receptor 5 phosphorylation in the rat striatum in vivo. J Neurosci Res 2016;94:329–38.
   PubMed Web of Science ®Google Scholar
• Ko HM, Lee SH, Kim KC, et al. The role of TLR4 and Fyn interaction on lipopolysaccharide-stimulated PAI-1 expression in astrocytes. Mol Neurobiol 2015;52:8–25.
   PubMed Web of Science ®Google Scholar
• Bain J, Plater L, Elliott M, et al. The selectivity of protein kinase inhibitors: a further update. Biochem J 2007;408:297–315.
   PubMed Web of Science ®Google Scholar
• Poli G, Martinelli A, Tuccinardi T. Computational approaches for the identification and optimization of Src family kinases inhibitors. Curr Med Chem 2014;21:3281–93.
   PubMed Web of Science ®Google Scholar
• Poli G, Tuccinardi T, Rizzolio F, et al. Identification of new Fyn kinase inhibitors using a FLAP-based approach. J Chem Inf Model 2013;53:2538–47.
   PubMed Web of Science ®Google Scholar
• Maestro, version 9.0. Portland (OR): Schrödinger Inc; 2009. Available from: https://www.schrodinger.com/
   Google Scholar
• Macromodel, version 9.7. Portland (OR): Schrödinger Inc; 2009. Available from: https://www.schrodinger.com/
   Google Scholar
• Tuccinardi T, Poli G, Romboli V, et al. Extensive consensus docking evaluation for ligand pose prediction and virtual screening studies. J Chem Inf Model 2014;54:2980–6.
   PubMed Web of Science ®Google Scholar
• Poli G, Martinelli A, Tuccinardi T. Reliability analysis and optimization of the consensus docking approach for the development of virtual screening studies. J Enzym Inhib Med Ch 2016;31:167–73.
   PubMed Web of Science ®Google Scholar
• Granchi C, Caligiuri I, Bertelli E, et al. Development of terphenyl-2-methyloxazol-5(4H)-one derivatives as selective reversible MAGL inhibitors. J Enzym Inhib Med Ch 2017;32:1240–52.
   PubMed Web of Science ®Google Scholar
• Morris GM, Huey R, Lindstrom W, et al. AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility. J Comput Chem 2009;30:2785–91.
   PubMed Web of Science ®Google Scholar
• DOCK, version 6.7. San Francisco (CA): Molecular Design Institute, University of California; 1998. Available from: http://dock.compbio.ucsf.edu/
   Google Scholar
• FRED, version 3.0.0. Santa Fe (NM): OpenEye Scientific Software, Inc.; 2013. Available from: https://www.eyesopen.com/
   Google Scholar
• OMEGA, version 2.4.6. Santa Fe (NM): OpenEye Scientific Software, Inc.; 2013. Available from: https://www.eyesopen.com/
   Google Scholar
• Hawkins PC, Skillman AG, Warren GL, et al. Conformer generation with OMEGA: algorithm and validation using high quality structures from the Protein Databank and Cambridge Structural Database. J Chem Inf Model 2010;50:572–84.
   PubMed Web of Science ®Google Scholar
• Hawkins PC, Nicholls A. Conformer generation with OMEGA: learning from the data set and the analysis of failures. J Chem Inf Model 2012;52:2919–36.
   PubMed Web of Science ®Google Scholar
• Verdonk ML, Cole JC, Hartshorn MJ, et al. Improved protein-ligand docking using GOLD. Proteins 2003;52:609–23.
   PubMed Web of Science ®Google Scholar
• Glide, version 5.0. Portland (OR): Schrödinger Inc; 2009. Available from: https://www.schrodinger.com/
   Google Scholar
• Trott O, Olson AJ. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem 2010;31:455–61.
   PubMed Web of Science ®Google Scholar
• Korb O, Monecke P, Hessler G, et al. pharmACOphore: multiple flexible ligand alignment based on ant colony optimization. J Chem Inf Model 2010;50:1669–81.
   PubMed Web of Science ®Google Scholar
• Tuccinardi T, Poli G, Dell'Agnello M, et al. Receptor-based virtual screening evaluation for the identification of estrogen receptor beta ligands. J Enzym Inhib Med Chem 2015;30:662–70.
   PubMed Web of Science ®Google Scholar
• Kinoshita T, Matsubara M, Ishiguro H, et al. Structure of human Fyn kinase domain complexed with staurosporine. Biochem Biophys Res Commun 2006;346:840–4.
   PubMed Web of Science ®Google Scholar
• Case DA, Berryman JT, Betz RM, et al. AMBER, version 14. San Francisco (CA): University of California; 2015. Available from: http://ambermd.org/
   Google Scholar
• York DM, Darden TA, Pedersen LG. The effect of long-range electrostatic interactions in simulations of macromolecular crystals - a comparison of the Ewald and truncated list methods. J Chem Phys 1993;99:8345–8.
   Web of Science ®Google Scholar
• Kollman PA, Massova I, Reyes C, et al. Calculating structures and free energies of complex molecules: combining molecular mechanics and continuum models. Acc Chem Res 2000;33:889–97.
   PubMed Web of Science ®Google Scholar
• Cincinelli R, Cassinelli G, Dallavalle S, et al. Synthesis, modeling, and RET protein kinase inhibitory activity of 3- and 4-substituted beta-carbolin-1-ones. J Med Chem 2008;51:7777–87.
   PubMed Web of Science ®Google Scholar
• Tuccinardi T, Granchi C, Iegre J, et al. Oxime-based inhibitors of glucose transporter 1 displaying antiproliferative effects in cancer cells. Bioorg Med Chem Lett 2013;23:6923–7.
   PubMed Web of Science ®Google Scholar
• Poli G, Giuntini N, Martinelli A, Tuccinardi T. Application of a FLAP-consensus docking mixed strategy for the identification of new fatty acid amide hydrolase inhibitors. J Chem Inf Model 2015;55:667–75.
   PubMed Web of Science ®Google Scholar
• Dal Piaz F, Vera Saltos MB, Franceschelli S, et al. Drug affinity responsive target stability (DARTS) identifies laurifolioside as a new clathrin heavy chain modulator. J Nat Prod 2016;79:2681–92.
   PubMed Web of Science ®Google Scholar
• Petrou A, Geronikaki A, Terzi E, et al. Inhibition of carbonic anhydrase isoforms I, II, IX and XII with secondary sulfonamides incorporating benzothiazole scaffolds. J Enzym Inhib Med Chem 2016;31:1306–11.
   PubMed Web of Science ®Google Scholar
• Kostic A, Lynch CD, Sheetz MP. Differential matrix rigidity response in breast cancer cell lines correlates with the tissue tropism. PLoS One 2009;4:e6361.
   PubMed Web of Science ®Google Scholar
• Green TP, Fennell M, Whittaker R, et al. Preclinical anticancer activity of the potent, oral Src inhibitor AZD0530. Mol Oncol 2009;3:248–61.
   PubMed Web of Science ®Google Scholar